NEXIEN BIOPHARMA, INC. (NXEN) is a publicly traded company in the Unknown sector. Across all available filings, 7 corporate insiders have executed 34 transactions totaling $1.4M, demonstrating a bearish sentiment with -$1.4M in net insider flow. The most recent transaction on May 23, 2024 involved a transaction of 2,000,000 shares valued at $0.
No significant insider buying has been recorded for NXEN in the recent period.
No significant insider selling has been recorded for NXEN in the recent period.
Based on recent SEC filings, insider sentiment for NXEN is bearish with an Insider Alignment Score of 0/100 and a net flow of -$1.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at NEXIEN BIOPHARMA, INC. (NXEN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 7 insiders are actively trading NXEN stock, having executed 34 transactions in the past 90 days. The most active insider is Jeffrey Friedland (Executive), who has made 3 transactions totaling $450.0K.
Get notified when executives and directors at NXEN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| May 23, 2024 | L. Wasoff Evan | Executive | Award | 2,000,000 | $N/A | $0 | |
| May 23, 2024 | S. Greenberg Richard | Executive | Award | 1,000,000 | $N/A | $0 | |
| Oct 31, 2023 | L. Wasoff Evan | Executive | Award | 250,000 | $N/A | $0 | |
| Oct 31, 2023 | S. Greenberg Richard | Executive | Award | 250,000 | $N/A | $0 | |
| Jul 25, 2023 | L. Wasoff Evan | Executive | Award | 250,000 | $N/A | $0 | |
| Jul 25, 2023 | S. Greenberg Richard | Executive | Award | 250,000 | $N/A | $0 | |
| Jul 25, 2023 | I. Goldfarb Robert | Executive | Award | 250,000 | $N/A | $0 | |
| Apr 1, 2023 | I. Goldfarb Robert | Executive | Award | 250,000 | $N/A | $0 | |
| Apr 1, 2023 | S. Greenberg Richard | Executive | Award | 250,000 | $N/A | $0 | |
| Apr 1, 2023 | L. Wasoff Evan | Executive | Award | 250,000 | $N/A | $0 | |
| Jan 17, 2023 | L. Wasoff Evan | Executive | Award | 250,000 | $N/A | $0 | |
| Jan 17, 2023 | S. Greenberg Richard | Executive | Award | 250,000 | $N/A | $0 | |
| Jan 17, 2023 | I. Goldfarb Robert | Executive | Award | 250,000 | $N/A | $0 | |
| Oct 17, 2022 | L. Wasoff Evan | Executive | Award | 250,000 | $N/A | $0 | |
| Oct 17, 2022 | S. Greenberg Richard | Executive | Award | 250,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 3 | $1.4M | 100.0% |
Award(A) | 28 | $0 | 0.0% |
Conversion(C) | 1 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Insider selling pressure at NEXIEN BIOPHARMA, INC. has increased, with 7 insiders executing 34 transactions across all time. Total sales of $1.4M significantly outpace purchases of $0, resulting in a net outflow of $1.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.